Data as of May 24
| +0.68 / +4.30%|
Repros Therapeutics Inc. is a development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health. The company's current product pipeline consists Androxal and Proellex. Androxal, the company's primary product candidate is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound being developed for men of reproductive age with low testosterone levels who want to improve or maintain their fertility and sperm function while being treated for low testosterone. Additionally, Repros plans to develop Androxal for men with adult-onset idiopathic hypogonadotrophic hypogonadism, or AIHH, with concomitant plasma glucose and lipid elevations, all of which are components of Metabolic Syndrome. Proellex is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Repros Therapeutics was founded on August 28, 1987 and is headquartered in the Woodlands, TX.
|Joseph S. Podolski||President, Chief Executive Officer & Director|
|Katherine A. Anderson, CPA||Secretary, Chief Financial & Accounting Officer|
|Jaye L. Thompson, PhD||Senior Vice President-Clinical & Regulatory|
|Donald Tredway, MD, PhD||Chief Medical Officer|
|Joachim F. Wernicke, PhD, MD||Chief Medical Officer|